PC
SAGE

PointState Capital’s Sage Therapeutics SAGE Stock Holding History

PointState Capital’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-36,200
Closed -$2.06M – 174
2021
Q2 		$2.06M Buy
+36,200
New +$2.56M 0.04% 110
2020
Q1 		– Sell
-13,600
Closed -$982K – 102
2019
Q4 		$982K Buy
+13,600
New +$1.67M 0.02% 102
2015
Q2 		– Sell
-102,450
Closed -$5.15M – 176
2015
Q1 		$5.15M Buy
+102,450
New +$4.4M 0.07% 95

Other funds holding SAGE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

PointState Capital's SAGE Position: Q3 2021 in Review

PointState Capital sold out of Sage Therapeutics (SAGE) in Q3 2021, closing a stake of 36,200 shares — an estimated $2.06M sold.

PointState Capital first reported a position in SAGE in Q1 2015 and held it in 3 quarters. The position peaked at $5.15M in Q1 2015. 225 funds tracked by Wall St. Rank hold SAGE as of Q3 2021.

  • PointState Capital reported no remaining Sage Therapeutics position as of Q3 2021 after selling out during the quarter.
  • PointState Capital sold 36,200 Sage Therapeutics shares in Q3 2021, an estimated $2.06M.
  • PointState Capital first reported a position in Sage Therapeutics in Q1 2015 and held it in 3 quarters.
  • PointState Capital's Sage Therapeutics position peaked at $5.15M in Q1 2015.
  • 225 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2021.

Based on PointState Capital's 13F filing for Q3 2021, filed 15 Nov 2021.